Alar Pharmaceuticals Inc.
Research Alar Pharmaceuticals Inc. (6785.TWO) on Bullrun: market cap TWD 5.72B, dividend yield 0.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6785.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 5.72B
- Dividend yield0.1%
- Financial periodQ2 2026
- RevenueTWD 1.25M
- Net incomeTWD 15.58M
- Free cash flow-TWD 25.73M
- Gross margin88.4%
Valuation Snapshot
latest market cap is TWD 5.72B; dividend yield is 0.1%.
Peer valuation comparison
Latest dividend yield is 0.12% versus a Healthcare sector median of 2.4% (95.0% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 5.72B | n/a | 0.1% | 0.1 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.1 TWD, yield 0.1%.
About Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc.
ETFs that hold Alar Pharmaceuticals Inc.
US-listed ETFs
Alar Pharmaceuticals Inc. is held by one US-listed ETF, going by the latest portfolio it filed with the SEC:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.01% | 0.65% |
Portfolios as filed with the SEC on Form N-PORT, dated June 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alar Pharmaceuticals Inc.'s market cap?
Alar Pharmaceuticals Inc.'s market capitalization is TWD 5.72B.
Does Alar Pharmaceuticals Inc. pay a dividend?
Alar Pharmaceuticals Inc. has a dividend yield of 0.1%.
What does Alar Pharmaceuticals Inc. do?
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.